
    
      This is an open-label (all people know the identity of the intervention), single-center,
      fixed-sequence, study of JNJ-42847922 in healthy participants. The study consists of 3
      Phases: Screening Phase (28 Days), open-label treatment Phase (40 Days) and follow up visit
      (7 to 14 Days after last study procedure). The duration of participation in the study for
      each participant is approximately 82 Days. Participants' safety will be monitored throughout
      the study.
    
  